Human Fatty Acid Binding Protein (HFABP) antibody and antigen (hapten, BSA/OVA conjugated)

 Download 

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-SMT-HFABP-Ag01	BSA-Human Fatty Acid Binding Protein (HFABP)	756
GMP-SMT-HFABP-Ag02	OVA-Human Fatty Acid Binding Protein (HFABP)	756
GMP-SMT-HFABP-Ab01	Anti-human Human Fatty Acid Binding Protein (HFABP) mouse monoclonal antibody (mAb)	1953
GMP-SMT-HFABP-Ab02	Anti-human Human Fatty Acid Binding Protein (HFABP) human monoclonal antibody (mAb)	1953

Size： 1mg | 10mg | 100mg

Product Description

Cat No. of Products	GMP-SMT-HFABP-Ag01
Product Name	BSA-Human Fatty Acid Binding Protein (HFABP)
Target/Biomarker	Human Fatty Acid Binding Protein (HFABP)
Alias of Target/Biomarker	FABP11, H-FABP, M-FABP, MDGI, O-FABP
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Human Fatty Acid Binding Protein (HFABP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in HFABP level test of Cardiovascular disease (metabolic syndrome, atherosclerosis, insulin resistance and low-grade inflammation) and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Human Fatty Acid Binding Protein (HFABP) / OVA-Human Fatty Acid Binding Protein (HFABP) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-HFABP-Ag02
Product Name	OVA-Human Fatty Acid Binding Protein (HFABP)
Target/Biomarker	Human Fatty Acid Binding Protein (HFABP)
Alias of Target/Biomarker	FABP11, H-FABP, M-FABP, MDGI, O-FABP
Expression platform	Synthetic
Isotypes	NA
Bioactivity validation	Human Fatty Acid Binding Protein (HFABP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in HFABP level test of Cardiovascular disease (metabolic syndrome, atherosclerosis, insulin resistance and low-grade inflammation) and related syndrome evaluation.
Tag	NA
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Human Fatty Acid Binding Protein (HFABP) / OVA-Human Fatty Acid Binding Protein (HFABP) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-HFABP-Ab01
Product Name	Anti-human Human Fatty Acid Binding Protein (HFABP) mouse monoclonal antibody (mAb)
Target/Biomarker	Human Fatty Acid Binding Protein (HFABP)
Alias of Target/Biomarker	FABP11, H-FABP, M-FABP, MDGI, O-FABP
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Human Fatty Acid Binding Protein (HFABP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in HFABP level test of Cardiovascular disease (metabolic syndrome, atherosclerosis, insulin resistance and low-grade inflammation) and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Human Fatty Acid Binding Protein (HFABP) / OVA-Human Fatty Acid Binding Protein (HFABP) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-SMT-HFABP-Ab02
Product Name	Anti-human Human Fatty Acid Binding Protein (HFABP) human monoclonal antibody (mAb)
Target/Biomarker	Human Fatty Acid Binding Protein (HFABP)
Alias of Target/Biomarker	FABP11, H-FABP, M-FABP, MDGI, O-FABP
Expression platform	Hybridoma
Isotypes	Mouse IgG
Bioactivity validation	Human Fatty Acid Binding Protein (HFABP) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in HFABP level test of Cardiovascular disease (metabolic syndrome, atherosclerosis, insulin resistance and low-grade inflammation) and related syndrome evaluation.
Tag	mFc
Products description	Competitive immunoassay-validated hapten-carrier conjugates BSA-Human Fatty Acid Binding Protein (HFABP) / OVA-Human Fatty Acid Binding Protein (HFABP) is Synthetic.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
Formulation	Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Target/Biomarker information

The fatty acid binding proteins (FABPs) are a family of transport proteins for fatty acids and other lipophilic substances such as eicosanoids and retinoids. These proteins are thought to facilitate the transfer of fatty acids between extracellular and intracellular membranes. FABP4 has been associated with several components of metabolic syndrome, atherosclerosis, insulin resistance and low-grade inflammation, and thus, it has been proposed as a cardiometabolic predictor for cardiovascular disease.

About GDU